ArticleBMC nephrology2025
Development of cardiovascular and all-cause mortality risk prediction models for maintenance hemodialysis patients based on metabolomics.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
introductionThe outcome of maintenance hemodialysis (MHD) remains poor, with cardiovascular death accounting for more than half of all-cause death cases. In this study, cardiovascular mortality and all-cause mortality prediction models were developed to investigate the predictive role of metabolites in MHD patients.
methodsClinical and metabolomics data of 135 hemodialysis patients from a single center were collected with a 6-year follow-up. Univariate Cox regression and random forest were respectively applied to preliminarily screen clinical and metabolomics characteristics, followed by multivariate Cox regression for identifying features predicting cardiovascular or all-cause mortality. Multivariate Cox proportional regression risk models were constructed using clinical, metabolomics, and combined features. Subgroup survival differences were compared via risk score stratification.
resultsThe combined model showed significant superiority in predicting cardiovascular mortality (3-year AUC = 0.901, 5-year AUC = 0.876), surpassing the clinical-only model (0.868/0.826) and metabolomics-only model (0.659/0.641). For all-cause mortality, the combined model demonstrated modest improvement (0.859/0.834) but still outperformed the metabolomics model (0.534/0.653). Thirty 5-fold cross-validations confirmed stable performance. High-risk groups had significantly higher cumulative mortality than low-risk groups (p < 0.0001).
conclusionThe metabolomics-alone model showed limited predictive performance, but its synergistic integration with clinical indicators further improved the predictive performance of mortality risk models, particularly for cardiovascular mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.